Al Hammadi Holding · TADAWUL:4007
Al Hammadi — H1 2025 Earnings Presentation
27 slides from Al Hammadi's earnings presentation, 2025
Slide 1: Results Presentation 1H 2025
Al Hammadi Holding Results Presentation 1H 2025
Slide 2: Table of Contents
Table of Contents I II III IV About Al Hammadi Market 1H 2025 Appendix Holding Overview Results Overview
Slide 3: About Al Hammadi Holding
About Al Hammadi Holding
Slide 4: An Integrated Healthcare Company
Al Hammadi is an integrated healthcare company and premier hospital operator providing world-class healthcare services to hundreds of thousands of local and foreign residents… An Integrated Healthcare Company 80%1 20%1 The company currently operates two hospitals in the Saudi Arabian Al Hammadi also
Slide 5: Coverage across the Saudi capital Riyadh
The Company enjoys widespread coverage spanning the entire Saudi capital Al Narjis Hospital2 4 Al Mansiyah Hospital3 5 Al Hammadi operates two state-of-the-art facilities, Al Nuzha and Al Nuzha 1 Al Suwaidi hospitals, strategically located in the heart of Riyadh. Hospital Over the coming five years,
Slide 6: Two premier hospitals in the heart of Riyadh
Al Hammadi operates two premier hospitals in the heart of Riyadh providing a wide range of world-class services to thousands of patients Al Nuzha Hospital Al Suwaidi Hospital Located in the northeast neighborhood of Riyadh, Al Nuzha Launched in 2015 and located in southwest Riyadh, Al Suwaidi Hospit
Slide 7: Growth plans to more than double capacity by 2030
The Group’s ambitious growth plans will see it more than double its capacity by 2030, enabling it to capitalize on the city’s growing healthcare demand Al Suwaidi Hospital Olaya Hospital Al Narjis Hospital Al Mansiyah Hospital Al Hammadi is looking to Originally launched in 1985, The Group plans to
Slide 8: Market Overview
Market Overview
Slide 9: Health Sector Transformation Plan and Vision 2030 healthcare targets
Guided by the Health Sector Transformation Plan, Saudi Arabia is developing a healthcare sector that is more comprehensive, effective, and integrated Some of Vision 2030 key healthcare targets Boost access to healthcare and Localize medical and Increase life expectancy Digitize healthcare insurance
Slide 10: Riyadh at the center of Vision 2030
Riyadh stands at the center of Vision 2030 as the city works to become a regional hub of business, culture and entertainment Riyadh stands as Vision 2030’s poster child, aiming to become a regional hub for Business Culture Entertainment Riyadh’s population and average incomes are rapidly expanding…
Slide 11: Rising demand for healthcare and hospital bed supply gap
Rapid movement of people and capital to the city is driving up demand for high-quality healthcare, opening up the door to vast growth opportunities for the private sector Rising population, income, insurance penetration levels is putting pressure on healthcare providers with the supply gap for hospi
Slide 12: 1H 2025 Results Overview
1H 2025 Results Overview
Slide 13: 1H 2025 Results Snapshot
1H 2025 Results Snapshot Al Hammadi closes the first half of 2025 with solid top-line growth, supported by growing patient volumes across both its Al Nuzha and Al Suweidi hospitals. Revenue Gross Profit Operating Profit Net Profit SAR 600 Million SAR 189 Million SAR 141 Million SAR 136 Million 1H 20
Slide 14: 1H 2025 Operational Review
1H 2025 Operational Review Al Hammadi achieves strong growth in volumes across both inpatient and outpatient segments, despite the price adjustments implemented as part of the Group’s broader strategy, reflecting robust demand on its service offerings. Inpatient Admissions | ‘000 Outpatient Examinat
Slide 15: 1H 2025 Consolidated Financial Performance (I/III)
1H 2025 Consolidated Financial Performance (I/III) Al Hammadi’s reported robust top-line growth for the quarter supported by rising volumes across both segments. Pharma Serve’s strategic decision to begin working with private sector players continues to boost revenue further. Al Hammadi is working t
Slide 16: 1H 2025 Consolidated Financial Performance (II/III)
1H 2025 Consolidated Financial Performance (II/III) The Group’s bottom-line was impacted by lower operating profitability reflecting the high base effect of one-off proceeds resulting from the sale of a vacant plot of land in Al Rayyan district, which had boosted net profit in 2Q2024. The rise in co
Slide 17: 1H 2025 Consolidated Financial Performance (III/III)
1H 2025 Consolidated Financial Performance (III/III) Al Hammadi’s bottom-line decline is attributable to the high base effect of one-off proceeds resulting from the sale of a vacant plot of land in Al Rayyan district, which had boosted profitability in Q2 2024. Net Profit before Zakat | SAR Mn Net P
Slide 18: Al Nuzha Hospital: 1H 2025 Performance
Al Nuzha Hospital: 1H 2025 Performance Al Nuzha posted a solid 11% y-o-y increase in revenue in 1H 2025. Top-line growth was supported by increasing inpatient and outpatient volumes, reflecting normalization post-price adjustments and robust demand on the facility’s offerings. The year-on-year incre
Slide 19: Al Suwaidi Hospital: 1H 2025 Performance
Al Suwaidi Hospital: 1H 2025 Performance Al Suweidi’s posted top-line growth in 1H 2025, driven by an 8% y-o-y increase in inpatient volumes, reflecting the normalization of volumes post price adjustments. Inpatient volumes at Al Suwaidi increased by a solid 8% y-o-y in 1H 2025, supported by the ant
Slide 20: Pharmaceuticals: 1H 2025 Performance Review
Pharmaceuticals: 1H 2025 Performance Review Al Hammadi’s pharmaceutical sales contributed 20% of consolidated revenue, recording SAR 119 million for 1H 2025, a 24% y-o-y increase. Revenue from In-House Pharmacies| SAR Mn Revenue from Pharma Serve| SAR Mn 120 30 ▲362.6% 100 ▲5% 25 80 20 ▲ 525.9% ▲2%
Slide 21: Appendix
Appendix
Slide 22: 1H 2025 Consolidated Income Statement
1H 2025 Consolidated Income Statement Y-o-Y Y-o-Y SAR mn Q2 2024 Q2 2025 1H 2024 1H 2025 Change Change Revenue 263.4 298.2 13.2% 540.5 600.1 11.0% Cost of revenue (177.7) (205.2) 15.5% (363.7) (410.1) 12.9% Gross Profit 85.7 93.0 8.5% 176.8 189.5 7.2% GPM 32.5% 31.2% -1.3pts 32.7% 31.6% -1.1pts Sell
Slide 23: 1H 2025 Consolidated Balance Sheet
1H 2025 Consolidated Balance Sheet SAR mn 31 December 2024 30 June 2025 ASSETS Non-current assets Property and equipment 1709.6 1687.6 Intangible assets and goodwill 27.1 27.6 Investment in associates 135.0 147.4 Total non-current assets 1871.7 1862.6 Current Assets Inventories 61.2 67.9 Other recei
Slide 24: 1H 2025 Consolidated Statement of Cash Flow
1H 2025 Consolidated Statement of Cash Flow SAR mn 30 June 2024 30 June 2025 OPERATING ACTIVITIES Net profit 181.9 135.9 Adjustments to reconcile net profit to cash flow Depreciation of property and equipment 43.5 42.0 Depreciation of ROU asset's 5.6 5.6 Amortization of intangible assets 0.3 0.3 Los
Slide 25: Sudair Pharmaceutical Company (SPC)
Sudair Pharmaceutical Company (SPC) was launched in 2014 with the goal of supporting the government’s ambitions for pharmaceutical and health security Over the last nine years, SPC has developed a comprehensive offering …all produced out of SPC’s state-of-the-art manufacturing facility covering a br
Slide 26: Saudi Vision 2030 pillars and targets
Saudi Arabia has embarked on a transformative journey setting the foundations for a stronger, more sustainable nation… Saudi Vision 2030 is predicated on three key pillars and sets out ambitious targets for the Kingdom 50% 80 years Share of non-oil GDP by Life expectancy by 2030 2030 10% USD 1.9 Tri
Slide 27: Transforming the healthcare sector under Vision 2030
Transforming the country’s healthcare sector is at the heart of Vision 2030 to ensure the country is ready to accommodate changing demand patterns and a shifting demographic profile… Saudi Arabia is home to a large, young, and rapidly growing population… …with a strong prevalence of non-communicable